ClinicalTrials.gg
Active, not recruitingNCT06784232Updated Jan 22, 2025

Alveolar Ridge Preservation: Biologically-oriented Alveolar Ridge Preservation Vs Modified Periosteal Inhibition

An observational study in Alveolar Ridge Preservation and Alveolar Bone Loss, sponsored by International Piezosurgery Academy. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by International Piezosurgery Academy · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-14

Among 14 studies in Alveolar Bone Loss by International Piezosurgery Academy — none open to participants now, 2 under way, none of them phase 3. Alveolar Bone Loss · International Piezosurgery Academy.

Started
2024
with 2 others
Observational
7 of 14
none open now
Registered
14th of 14
by date

Among the 14 studies in Alveolar Bone Loss by International Piezosurgery Academy, this one is one of 3 that started in 2024, is one of 7 observational ones, and was the 14th registered.

Alveolar Bone Loss

319 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.

Browse Alveolar Bone Loss studies →

Open to participants now

None of the 14 studies in Alveolar Bone Loss by International Piezosurgery Academy is open now. The open studies under Alveolar Bone Loss, anywhere →

Where they have run

Who these studies take

Of the 47 Alveolar Bone Loss studies recruiting now, 19 (40%) set no upper age limit and 22 (47%) stop at 75 or younger; 4 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Alveolar Bone Loss by International Piezosurgery Academy as a file.
02

Study summary

The modified periosteal inhibition technique has been proposed as an alternative to limit crestal resorption following tooth extraction in sockets with a residual vestibular thickness of \<1 mm. This technique aims to prevent osteolytic activity on the external surface of a post-extraction socket by applying a 0.5 mm-thick soft cortical plate of porcine origin, secured with fibrin glue. By avoiding the placement of bone graft material inside the socket, the technique seeks to effectively counteract bone remodeling, achieving minimal reduction in the size of the alveolar crest.

The aim is to evaluate the effectiveness of the modified periosteal inhibition technique in preserving the dimensions of the alveolar ridge after tooth extraction, by comparing it with the Biologically-oriented Alveolar Ridge Preservation technique.

Read the detailed description

The primary objective of the study is to clinically compare the effect on the preservation of the alveolar ridge using the modified periosteal inhibition technique and the Biologically-oriented Alveolar Ridge Preservation technique.

The secondary objective is the collection of histological and histomorphometric data that allow to evaluate the quality and quantity of newly formed bone.

Study design: Observational study of a prospective non-profit cohort.

Study population: The study will be conducted in an outpatient hospital setting.

Number of patients to be enrolled to compare modified periosteal inhibition technique and BARP: 30 patients in the University of Trieste including dropouts.

Enrollment procedure: all patients who meet the inclusion and exclusion criteria will be enrolled in the study following the administration of the Information Sheet and the acquisition of informed consent.

The choice of the alveolar ridge preservation protocol will be motivated by the clinicians experience and the patients preference among those currently validated.

BARP: under local anesthesia, the compromised tooth will be extracted atraumatically without raising a flap. After granulation tissue removal, the socket will be filled with a collagen sponge (deep collagen layer) up to 4 to 5 mm from the most coronal extensions of the buccal crest to create a support for the intra-alveolar graft. A bovine derived xenograft will be placed on top of the collagen sponge to fill the coronal part of the socket, avoiding overfilling (graft layer). Socket sealing will be performed with a new layer of collagen sponge that will be placed over the exposed portion of the graft layer and firmly held by sutures.

Modified periosteal inhibition technique: under local anesthesia, an atraumatic tooth extraction will be performed, ensuring the preservation of the buccal bone. After granulation tissue removal, papillae incisions will be made, followed by an intra-sulcular incision along the buccal side of the socket, extending to the mesial and distal mid-tooth regions. A full-thickness flap will be elevated, creating sufficient space within the socket for the insertion of the cortical lamina. The lamina will be trimmed to the required shape, extending to the mesial and distal edges of the extraction socket. A few drops of human fibrin glue (2-3) will be applied to the cortical lamina, which will then be gently pressed against the buccal bone to secure it in place. A collagen sponge will be placed inside the socket to stabilize the clot and held in position with a suture.

For all patients, after 26 weeks of healing, a mucoperiosteal flap will be raised to expose the target site and a titanium implant will be inserted. During this phase, using a core drill to prepare the implant site, it will also be functional to obtain a bone sample that will be subsequently analyzed.

Study Outcomes

The primary endpoint is the width of the alveolar ridge, which will be assessed in two stages:

T0: initial condition of the alveolar ridge, measured before performing surgery; T1: final condition of the alveolar ridge, measured before implant insertion at 26 weeks of healing from surgery.

The primary endpoint will be classified as follows. The secondary endpoints are represented by histomorphometric variables: newly formed mineralized tissue (New bone/Total volume), graft residues (RG/TV), newly formed non-mineralized tissue (Nonmineralised tissue/Total volume), total mineralized tissue that will be assessed at twenty-six weeks of healing (Mineralised tissue/total volume) evaluated as means and standard deviations and with χ2 test.

The primary endpoint will then be assessed in relation to complications and adverse events, such as: soft tissue dehiscence; graft exposure; graft loss and wound infections.

The width of the alveolar ridge will be measured linearly and volumetrically, using digital scans processed by a 3D scanning software (Geomagic Control X, 3D System, Morrisville, USA) at the University of Trieste.

The data collected at follow-up and the outcome data are based on a clinical evaluation, considering the possible presence of complications and adverse events.

The histological and histomorphometric analysis of all samples will be performed by one of the authors, blinded to the study design and the origin of the biopsy. The biopsies, left inside the core drills to maintain the orientation of the bone core, will be rinsed with a cold 5% glucose solution to remove blood residues while maintaining the correct osmolarity (278 mOsm/L). The samples will then be fixed for 3 days in a 10% buffered formalin solution at pH 7.2 and then processed for histological and histomorphometric evaluation at the Bone Lab, University of Trieste. After this, the samples will be delivered to specialized and authorized companies for disposal, according to current legislation.

Collected data variables and sources The following variables will be collected for each enrolled patient/participant: width of the alveolar ridge; newly formed mineralized tissue; graft residues; non-mineralized newly formed tissue and total mineralized tissue.

Histological and histomorphometric analysis of all samples will be performed by one of the authors, blinded to the study design and biopsy origin. Biopsies, left inside the core drills to maintain the orientation of the bone core, will be rinsed with a cold 5% glucose solution to remove blood residues while maintaining the correct osmolarity (278 mOsm/L). Samples will then be fixed for 3 days in a 10% buffered formalin solution at pH 7.2 and then dehydrated in ascending series of alcohol rinses. After 5 days of preinfiltration in a 50% resin/alcohol solution, biopsies will be removed from the core drills and sample infiltration will be completed with methacrylate resin. After 12 days of polymerization, the samples will be cut along their longitudinal axis using a high-precision silicon carbide disc at 50 μm and then finished under running water with a series of polishing discs at approximately 30 ± 10 μm. They will then be mounted on slides and stained with acid fuchsin, toluidine blue and Von Kossa.

Following histological and histomorphometric analyses, the samples will be delivered to specialized and authorized companies for disposal, according to current legislation.

Statistical plan The statistical analysis will be performed by means of a computerized statistical package (SigmaStat 3.5, SPSS Inc., Germany). The data will be expressed as mean ± standard deviation and median (interquartile range), respectively, for parametric and non-parametric values.

Sample size calculation The aim of the study is to clinically compare different alveolar ridge preservation techniques. Considering the outcomes of previously published studies, it was calculated that will be necessary to recruit 15 patients for each group to obtain a statistically significant result through a comparison between subpopulations with a statistical power of 95% and a significance of 0.05.

03

Conditions studied

  • Alveolar Ridge Preservation
  • Alveolar Bone Loss

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will be conducted in an outpatient hospital setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 80 years;
  • Single-rooted tooth with indication for extraction with sockets having a residual thickness of \<1 mm in the first 3 mm of the buccal residual crest presenting adjacent teeth;
  • 3;
  • Periodontal health or stability;
  • Signature of .

Exclusion criteria

Exclusion Criteria:

  • Presence of periapical cystic lesions at the intervention sites;
  • Loss of bone tissue extending to the apical third on radiographic examination;
  • Extraction of adjacent teeth within a period ranging from 6 months prior to 6 months after the extraction;
  • Lack of one or more walls of the post-extraction socket;
  • Presence of general for oral surgery;
  • Presence of inflammatory and diseases;
  • Uncontrolled diabetes ( 7%);
  • History of tumors requiring chemotherapy or radiotherapy in the last 5 years;
  • Previous therapy with bisphosphonates or high-dose therapy;
  • Smoking (10 cigarettes/day);
  • Allergy to bovine collagen;
  • Pregnancy or breastfeeding;
  • Lack of compliance.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • BARP

    collagen-bonegraft-collagen

    Procedure: BARP

  • Modified Periosteal Inhibition Technique

    cortical lamina, human fibrin glue and collagen

    Procedure: Modified Periosteal Inhibition Technique

Interventions

  • ProcedureBARP

    deep layers of collagen, medium-superficial heterologous bone graft, superficial collagen layer

  • ProcedureModified Periosteal Inhibition Technique

    Cortical lamina stabilized with human fibrin glue to preserve the buccal wall of the socket. The socket was then filled with collagen.

06

What researchers measure

Primary outcomes

  1. ridge width reduction

    optical scanning comparison measured in millimetres at the mid-buccal and mid-palatal aspect of the socket

    Time frame: 26 weeks after tooth extraction and preservation tecnhique

  2. ridge height reduction

    optical scanning comparison measured in millimetres at the mid-buccal, mid-palatal, mesial and distal aspect of the socket

    Time frame: 26 weeks after tooth extraction and preservation tecnhique

Secondary outcomes

  1. histologic and histomorphometric analysis of new bone formation

    percentage of newly formed bone area to total measured area

    Time frame: 26 weeks after tooth extraction and preservation tecnhique

  2. histologic and histomorphometric analysis of residual graft particles

    percentage of graft particles area to total measured area

    Time frame: 26 weeks after tooth extraction and preservation tecnhique

  3. histologic and histomorphometric analysis of marrow spaces

    percentage of soft tissue area to total measured area

    Time frame: 26 weeks after tooth extraction and preservation tecnhique

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.

Of 22 observational studies under Alveolar Bone Loss, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 27. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2025
First posted
Jan 20, 2025
StartActual
Dec 1, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06784232
Lead sponsor
International Piezosurgery Academy
Collaborators
University of Trieste
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
Dec 1, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jan 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion